Litigating the Drug Price Competition and Patent Term Restoration Act of 1984

Litigating the Drug Price Competition and Patent Term Restoration Act of 1984

DSpace/Manakin Repository

Litigating the Drug Price Competition and Patent Term Restoration Act of 1984

dc.contributor.advisor	Hutt, Peter Barton	en_US
dc.contributor.author	Reines, Emily B.	en_US
dc.date.accessioned	2012-06-07T04:33:05Z
dc.date.issued	2000	en_US
dc.identifier.citation	Litigating the Drug Price Competition and Patent Term Restoration Act of 1984 (2000 Third Year Paper)	en
dc.identifier.uri	http://nrs.harvard.edu/urn-3:HUL.InstRepos:8846791
dc.description.abstract	The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act in honor of its sponsors Senator Orrin Hatch and Representative Henry Waxman, was enacted in an attempt to reconcile two seemingly contradictory policy goals. The Act represented a compromise between the interests of generic drug manufacturers and the competing interests of the "pioneer" drug manufacturers who research and develop novel drug products. Thus, the Act was designed to improve the availability of inexpensive generic drugs, while maintaining sufficient incentives for investment in new drug development. The Hatch-Waxman Act creates a complex statutory framework, such that many problems and debates have arisen surrounding its implementation. This paper gives an overview of the issues that have been litigated under the Hatch-Waxman Act in the nearly sixteen years since its enactment.	en
dc.language.iso	en_US	en
dash.license	LAA	en_US
dc.subject	Food and Drug Law	en
dc.subject	FDA	en
dc.subject	drug	en
dc.subject	Hatch-Waxman	en
dc.subject	litigation	en
dc.subject	patent	en
dc.title	Litigating the Drug Price Competition and Patent Term Restoration Act of 1984	en
dc.type	Paper (for course/seminar/workshop)	en_US
dc.date.available	2012-06-07T04:33:05Z